August 30, 2019 10:14 AM EDTUpdated 11:00 AM

Paratek publishes positive PhIII data on approved Nuzyra; Allergan settles opioid lawsuits in two Ohio counties

ENDPOINTS

→ Paratek Pharmaceuticals‘ $PRTK Nuzyra (omadacycline) has met all primary and secondary clinical study endpoints in their OASIS-2 Phase III clinical trial, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Paratek publishes positive PhIII data on approved Nuzyra; Allergan settles opioid lawsuits in two Ohio counties

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Paratek pub­lish­es pos­i­tive PhI­II da­ta on ap­proved Nuzyra; Al­ler­gan set­tles opi­oid law­suits in two Ohio coun­ties

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Paratek publishes positive PhIII data on approved Nuzyra; Allergan settles opioid lawsuits in two Ohio counties